

Supplementary table 6. 2^o Sensitivity analysis. Regression analysis by disease comparing patients who discontinued therapy according to clinical remission vs patients who continue

		RA			AS			PsA		
		OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
Female sex		1.23	(0.12-12.22)	0.861	0.45	(0.14-1.48)	0.189	0.68	(0.31-1.50)	0.339
Age		1.01	(0.96-1.06)	0.678	0.96	(0.92-1.00)	0.046	1.00	(0.97-1.04)	0.932
TNF-i		0.71	(0.14-3.54)	0.675	-	-	-	-	-	-
Smoking (ref smoker)	Non-smoker	2.75	(0.29-26.10)	0.378	2.54	(0.68-9.47)	0.166	2.01	(0.65-6.23)	0.224
	Ex-smoker	1.17	(0.06-22.96)	0.916	-	-	-	0.61	(0.06-5.92)	0.668
Order of treatment		4.96	(1.16-21.20)	0.031	1.02	(0.30-3.48)	0.974	1.96	(0.85-4.52)	0.113
Disease duration		0.97	(0.88-1.06)	0.471	0.93	(0.85-1.03)	0.150	0.98	(0.92-1.04)	0.523
ACPA (ref negative)	Positive	0.11	(0.02-0.51)	0.005	-	-	-	-	-	-
HLA B27 (ref negative)	Positive	-	-	-	0.38	(0.11-1.37)	0.140	1.30	(0.42-4.01)	0.646
Time on treatment with the previous biologic agent		1.03	(1.01-1.05)	0.001	-	-	-	1.01	(1.00-1.02)	0.011
Year of discontinuation of treatment		0.87	(0.71-1.05)	0.144	0.90	(0.80-1.02)	0.109	0.99	(0.90-1.09)	0.840

Footnote to Table 3: OR: odds ratio. 95% CI: 95% confidence interval. TNF-i: tumor necrosis factor alfa inhibitor. RA: rheumatoid arthritis; AS: ankylosing spondylitis; PsA: psoriatic arthritis; RF rheumatoid factor; ACPA: anti-citrullinated peptide antibody.

Note: There were no ex-smokers for AS.